Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in myonuclei | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 7 Parkinson's papers of 9,484 | 0.73 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 3304
Sealed predictions
- SACS in dopamine neurons, braak-0.32 (p 0.407) → -0.33 (p 0.393)receipt 3312
Swarm cases
receipt 3312: SACS in dopamine neurons, braak
- power
- full sample -0.31 (p 0.218, n 18), 95% CI -0.68 to +0.19. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.269, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.21 (p 0.393, n 18). could be the mix.
- skeptic
- leave-one-out range -0.42 to -0.21, sign flips 0; without severely affected donors -0.31 (p 0.218, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SACS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts